Bevacizumab plus Capecitabine as Maintenance Therapy after Initial Bevacizumab plus XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase Ill 'Stop and Go' Study Results - A Turkish Oncology Group Trial

Basit Öğe Kaydı
dc.contributor.authorYalcin, Suayib
dc.contributor.authorUslu, Ruchan
dc.contributor.authorDane, Faysal
dc.contributor.authorYilmaz, Ugur
dc.contributor.authorZengin, Nurullah
dc.contributor.authorBuyukunal, Evin
dc.contributor.authorBuyukberber, Suleyman
dc.contributor.authorCamci, Celalettin
dc.contributor.authorSencan, Orhan
dc.contributor.authorKilickap, Sadettin
dc.contributor.authorOzdener, Fatih
dc.contributor.authorCevik, Duygu
dc.date.accessioned2019-10-27T21:55:37Z
dc.date.available2019-10-27T21:55:37Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine following induction with bevacizumab + capecitabine + oxaliplatin (XELOX) versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer (mCRC). Methods: Patients received either bevacizumab (7.5 mg/kg) + XELOX (capecitabine 1,000 mg/m(2) twice daily on days 1-14 + oxaliplatin 130 mg/m2 on day 1 every 3 weeks) until disease progression (arm A) or the same doses of bevacizumab + XELOX for 6 cycles followed by bevacizumab + capecitabine until disease progression (arm B). The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR) and safety. Results: One hundred and twenty-three patients were randomized. Treatment compliance was similar in both groups. Median PFS was significantly longer for arm B than for arm A (11.0 vs. 8.3 months; p = 0.002). There was no significant difference between the two arms for ORR (66.7 vs. 59.0%; p = 0.861) or median OS (23.8 vs. 20.2 months; p = 0.100). Tolerability was acceptable in both treatment arms; the most frequent grade 3/4 treatment-related adverse events (arm B vs. arm A) were fatigue (6.6 vs. 16.1%), diarrhoea (3.3 vs. 11.3%), anorexia (3.3 vs. 11.3%), and neuropathy (1.6 vs. 8.1%). Conclusions: Maintenance therapy with bevacizumab + capecitabine can be considered an appropriate option following induction bevacizunnab + XELOX in patients with mCRC instead of continuation of bevacizumab + XELOX. (C) 2013 S. Karger AG, Baselen_US
dc.description.sponsorshipF. Hoffmann-La RocheHoffmann-La Rocheen_US
dc.description.sponsorshipFunding for the study and support for third-party writing assistance for the manuscript were provided by F. Hoffmann-La Roche.en_US
dc.identifier.doi10.1159/000355914en_US
dc.identifier.endpage335en_US
dc.identifier.issn0030-2414
dc.identifier.issn1423-0232
dc.identifier.issue6en_US
dc.identifier.pmid24247559en_US
dc.identifier.startpage328en_US
dc.identifier.urihttps://doi.org/10.1159/000355914
dc.identifier.urihttps://hdl.handle.net/11454/48249
dc.identifier.volume85en_US
dc.identifier.wosWOS:000329268000003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBevacizumaben_US
dc.subjectCapecitabineen_US
dc.subjectOxaliplatinen_US
dc.subjectMetastatic colorectal canceren_US
dc.subjectMaintenance therapyen_US
dc.titleBevacizumab plus Capecitabine as Maintenance Therapy after Initial Bevacizumab plus XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase Ill 'Stop and Go' Study Results - A Turkish Oncology Group Trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu